Merck is in a tight spot, balancing blockbuster Keytruda’s looming 2028 patent cliff and rough seas in China’s market.

Merck & Co – known as MSD outside the US and Canada – has shared promising results from a late-stage study of its anti-PD-1 ...

Merck’s Keytruda, with more than 40 approved indications, hasn’t yet been able to crack specifically into ovarian cancer. | ...

Merck offers a 4.2% dividend yield but faces uncertainty with KEYTRUDA's LOE. Click here to find out why MRK stock is a Hold.

Merck is expanding in oncology, immunology, and vaccines through acquisitions and R&D. Find out what makes MRK a stable GARP ...

US drugmaker Merck &Co will present data on the use of its PD-1 inhibitor Keytruda in four new cancer types later this week as it jostles for territory in the fast-growing immuno-oncology sector.

Leerink Partners previews the drugs likely to be subject to the Inflation Reduction Act’s next price negotiations as the ...

Merck (NYSE:MRK) announced Thursday that its bestselling therapy, Keytruda, as part of a combination regimen, reached the ...

Merck's Phase 3 trial of Keytruda plus chemo met progression-free survival and overall survival goals in platinum-resistant ...

Merck & Co’s attempts to move its checkpoint inhibitor Keytruda into prostate cancer have been blocked once again, continuing a run of disappointing studies with immunotherapies in the disease.

Merck & Co. ‘s planned debut this fall of an injectable form of its breakthrough cancer treatment Keytruda will simplify care, expand access, and save more lives, the company says. But by shifting ...